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 ■ Abstract 
AIM: To evaluate critically the current guidelines for foot 
screening in patients with diabetes, and to examine their 
relevance in terms of advancement in clinical practice, im-
provement in technology, and change in socio-cultural struc-
ture. METHODS: A structured literature search was con-
ducted in Pubmed/Medline, CINAHL, Cochrane Register of 
Controlled Trials, and Google between January 2011 and 
January 2015 using the keywords ‘(Diabetes) AND (Foot 
Screening) AND (Guidelines)’. RESULTS: Ten complete 
diabetes foot screening guidelines were identified and se-
lected for analysis. Six of them included the full-process 
guidelines recommended by the International Diabetes Fed-
eration. Evaluation of the existing diabetes foot screening 
guidelines showed substantial variability in terms of differ-
ent evidence-based methods and grading systems to achieve 
targets, making it difficult to compare the guidelines. In 
some of the guidelines, it is unclear how the authors have 
derived the recommendations, i.e. on which study results 
they are based, making it difficult for the users to under-
stand them. CONCLUSIONS: Limitations of currently avail-
able guidelines and lack of evidence on which the guidelines 
are based are responsible for the current gaps between 
guidelines, standard clinical practice, and development of 
complications. For the development of standard recommen-
dations and everyday clinical practice, it will be necessary to 
pay more attention to both the limitations of guidelines and 
the underlying evidence. 
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1. Introduction 
 
 iabetes contributes to approximately 80% of 
 the 120,000 non-traumatic amputations per- 
 formed yearly in the US. While some studies 
reported that every 20 seconds a limb is ampu-
tated somewhere in the world, others highlighted 
that the implementation of a structured diabetes 
foot screening program could achieve a 75% reduc-
tion in amputation rates [1]. 
Screening for diabetes involves the identifica-
tion of asymptomatic individuals who are at high 
risk of developing the disease or its complications 
through appropriate screening tests. Guidelines 
are an essential component of achieving quality in 
the care of diabetes [2]. These guidelines are de-
vised to define standards for care. They should use 
evidence-based interventions to provide health 
care professionals, policy makers, administrators, 
and people living with diabetes with a set of rec-
ommendations for prevention, diagnosis, and 
management of type 2 diabetes and its complica-
tions. A number of studies have demonstrated that 
patient outcomes improve when evidence-based 
guideline recommendations are applied in clinical 
practice [3]. 
Serious diabetic foot complications can be de-
layed and even prevented with appropriate, care-
ful, and reliable screening and management stan-
dards. Several countries and organizations such as 
WHO and IDF have made suggestions with the 
aim of reducing the rate of amputations by up to 
50%. It is speculated that implementing a foot 
screening and protection program for patients at  
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risk of ulceration may reduce both morbidity and 
cost [4]. However, a diabetic foot screening tool 
needs to be evidence-based and relevant to the 
characteristics of the target population [5]. Despite 
the advancement in technology, biomechanical 
modeling, and other treatment innovations, the re-
finement of current foot screening guidelines is 
paramount to prevent amputations and to pre-
serve limb function in high-risk patients. 
During the last decade, a number of diabetes 
foot screening guidelines and expert consensus 
documents have been formulated by various or-
ganizations and experts in the field. It is normally 
expected that effective implementation of guide-
lines requires 3 interrelated aspects: 
 
1. An explicit assessment of the quality of the 
available medical evidence. 
2. Application of clinical judgment in the care 
of individual patients. 
3. Elicitation and acceptance of patient prefer-
ences via shared decision-making. 
 
However, most of the current guidelines ad-
dress only the first of these 3 aspects (quality of 
evidence). In this regard, it is important to note 
that effective implementation requires the tailor-
ing of guidelines to the individual patient because 
“evidence alone is never sufficient to make a clini-
cal decision.” [6]. Except a few examples, current 
guidelines do not address patient preferences or 
include tools for shared decision-making. Although 
patient preferences have not historically been at 
the heart of evidence-based medicine [7], an 
emerging consensus is that patient preferences 
should be included [8], particularly when evidence 
is weak or incomplete. 
2. Justification for the study 
The practice of diabetes care is still not optimal, 
and it is far from being consistent both within and 
between countries [2]. The high number of differ-
ent and partly contradictory recommendations and 
guidelines existing today, and the discrepancies 
between different organizations and countries, 
may cause confusion on the part of both practicing 
health care professionals and organizations which 
attempt to develop local clinical guidelines. Fur-
ther confusion in clinical care is generated by the 
high number of proposed diabetes foot screening 
methods that may be useful in the identification of 
high-risk patients [9]. On the other hand, changes 
in the pattern of disease progression and outcome, 
environment, and anthropometry, in combination 
with new developments in technology for both 
measurement and treatment advocate for more ac-
curate and refined diabetes foot screening guide-
lines. 
The aim of this study was to evaluate critically 
the existing foot screening guidelines, with a view 
to examining their completeness in terms of ad-
vancement in clinical practice, improvements in 
technology, and changes in socio-cultural struc-
ture. This should result in the improvement of ex-
isting screening guidelines and eventually save 
limbs. Whilst analyzing the similarities and differ-
ences within various guidelines, this report aims 
particularly to highlight the deficiencies in guide-
lines. It should help to identify aspects for which 
there is sufficient agreement, highlight specific 
limitations in present guidelines, and address fu-
ture changes and research which may support the 
development of more accurate and reliable guide-
lines. 
3. Methods 
3.1 Protocol 
In this study, the following protocol was 
adopted, as recommended by the IDF [2]: 
Abbreviations: 
 
ABI ankle brachial index 
ABPI  ankle brachial pressure index 
ADA American Diabetes Association 
AHCPR Agency for Health Care Policy and Research 
CDA Canadian Diabetes Association 
CINAHL Cumulative Index to Nursing and Allied 
Health Literature 
DDG Deutsche Diabetes Gesellschaft 
GRADE Grading of Recommendations Assessment, 
Development, and Evaluation 
ICSI Institute for Clinical Systems Improvement 
IDF Interntional Diabetes Federation 
IWGDF International Working Group on the Diabetic 
Foot 
NG19 National Guideline 19 
NHMRC National Health and Medical Research 
Council 
NHS National Health Service 
NICE National Institute for Health and Care Ex-
cellence 
NZSSD New Zealand Society for the Study of Diabe-
tes 
PAD  peripheral arterial disease 
PPG photoplethysmography 
QUADAS Quality Assessment Tool for Diagnostic Ac-
curacy Studies 
RCT randomized controlled trial 
SIGN Scottish Intercollegiate Guidelines Network 
TCPO2 transcutaneous oxygen 
WHO World Health Organization 
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1. Development of the research question. The 
proposed question for this study was as fol-
lows: Are the currently available foot screen-
ing guidelines sufficient to identify reliably 
patients at risk of amputations? 
2. Use of the full-process diabetes foot screen-
ing guidelines, as proposed by the IDF, as 
reference guideline [2]. 
3. Search for other guidelines relating to the 
research question. 
4. Search for recent evidence in reviews, meta-
analyses, and major research studies. 
5. Evaluation of the quality and relevance of 
the available evidence and guidelines. 
6. Comparison of relevant guidelines in rela-
tion to their ability in identifying patients at 
risk and preventing severe diabetes foot 
complications. 
Table 1. List of guidelines for diabetic foot screening included in the study 
 
Guideline Guideline provider Year Reference to guideline Grading system used Reference to 
grading system  
National evidence-based 
guideline 
National Health and 
Medical Research Coun-
cil (NHMRC), Australia 
2011 NHMRC, 2011 [9] Own (NHMRC) NHMRC, 2011, pp. 
10-12 [9] 
Clinical practice guidelines 
for the prevention and man-
agement of diabetes in Can-
ada 
Canadian Diabetes Asso-
ciation (CDA), Canada 
2013 CDA, 2013 [10] Own (CDA) CDA, 2013 [11] 
Diabetic foot problems: pre-
vention and management. 
NICE guideline NG19 
National Institute for 
Health and Care Excel-
lence (NICE), England 
and Wales 
2014, 
updated 
2016 
NICE, 2014 [12] Own (NICE). Adapted 
from: US Agency for 
Healthcare Policy and 
Research Classification 
and Clinical Outcomes 
Group of the NHS Execu-
tive (1996) 
NICE, 2005 [13] 
Clinical practice guidelines: 
diabetic foot care 
Deutsche Diabetes Ge-
sellschaft (DDG), Ger-
many 
2014 DDG, 2014 [14] According to: Agency for 
Health Care Policy and 
Research (AHCPR), 1992, 
and SIGN, 1996 
DDG, 2006 [15] 
Management of diabetes: a 
national clinical guide 
Scottish Intercollegiate 
Guidelines Network 
(SIGN), Scotland 
2013 SIGN, 2014, pp. 104 ff 
[16] 
Own (SIGN) SIGN, 2014, p. 1 
[16] 
Diagnosis and management 
of type 2 diabetes mellitus 
in adults 
Institute for Clinical Sys-
tems Improvement 
(ICSI), USA 
2014 ICSI, 1014 [17] Grading of Recommenda-
tions Assessment, Devel-
opment and Evaluation 
(GRADE) system 
Kavanagh, 2009 
[18] 
Foot Screening Guidelines American Diabetes Asso-
ciation (ADA), USA 
2014, 
updated 
2016 
ADA, 2014, S47-S49 [19] Own (ADA) ADA, 2014, S15 
[19] 
IWGDF Guidance on the 
management and preven-
tion of foot problems in dia-
betes 
International Working 
Group on the Diabetic 
Foot (IWGDF) 
2015 IWGDF, 2015 [20]; Bak-
ker et al., 2011 [21] 
(short version of the 
guideline which is 
based on 7 reviews)* 
GRADE, SIGN* Kavanagh 
(GRADE), 2009 
[18], SIGN, 2014, 
p. 1 [16]. 
Global guideline for type 2 
diabetes  
International Diabetes 
Federation (IDF) 
2012, 
updated 
2015 
IDF, 2012 [29] Own (IDF) IDF, 2003 [2] 
Diabetes Foot Screening 
and Risk Stratification Tool 
New Zealand Society for 
the Study of Diabetes 
(NZSSD) - Podiatry Spe-
cial Interest Group 
2014 http://www.nzssd.org.nz/healthpr
ofs/14%2007%20Pri-
mary%20diabetes%20foot%20screen
ing%20and%20referral%20pathways.
pdf 
Guideline and grading 
adopted from SIGN risk 
stratification system 
 
 
 
Legend: * Guideline based on 7 systematic reviews created by IWGDF working groups. The reviews are related to different topics: 1) preven-
tion [22], 2) footwear [23], 3) PAD diagnosis [24], 4) PAD prognosis [25], 5) PAD therapy [26], 6) infection [27], and 7) wound healing [28]. 
Each group applied its own grading system, usually either the GRADE or the SIGN system. See http://iwgdf.org/guidelines-2/systematic-
reviews/. Abbreviations: GRADE – Grading of Recommendations Assessment, Development, and Evaluation, PAD – peripheral artery disease. 
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3.2 Search strategy and guidelines included 
Six full-process guidelines were automatically 
included in the study. These guidelines involved a 
complete and systematic development of the clini-
cal questions addressed, and provided recommen-
dations supported by scientific and formal evi-
dence, even if at different degrees of quality.  
After including the six guidelines, searches 
were performed to identify other possible guide-
lines and research evidence that are available for 
diabetes foot screening protocols. All searches were 
limited to the English language. The following 
electronic databases were retrieved between Janu-
ary 2011 and January 2015: Pubmed/Medline, CI-
NAHL, Cochrane Register of Controlled Trials, 
and Google Scholar. The search term ‘(Diabetes) 
AND (Foot Screening) AND (Guidelines)’ was 
used, and studies involving adult human partici-
pants living with diabetes were pre-selected. 
Guidelines and research evidence were considered 
for inclusion if they addressed aspects of diabetes 
foot screening, management, prevention, and edu-
cation relating to the foot care of people with type 
2 diabetes. The titles and abstracts of the articles 
containing the guidelines identified by the search 
strategy were screened by one author (CF) to iden-
tify potentially eligible articles. If it was unclear 
from the title or abstract whether an article should 
be included, the full-text article was retrieved, and 
a consensus between the three authors (CF, AG, 
NC) was induced. 
The search for full-text articles and guidelines 
resulted in the following outcome: 
 
- Sixty-eight documents were found in Pub-
med and 4 documents in Cochrane Register 
of Controlled Trials. However, when manu-
ally searched and evaluated there was no 
relevant citations amongst these articles 
which reported diabetes foot screening 
guidelines. So, these 72 articles were ex-
cluded. 
- Four relevant diabetes foot screening guide-
lines were identified by manual search in 
Google Scholar. 
- Six full-process guidelines proposed by the 
IDF (see section 3.1) were included. 
 
Thus, ten relevant foot screening guidelines 
were finally included. Table 1 lists the ten guide-
lines on foot screening along with the details of the 
publishing organization, and shows the references 
to the guidelines and the evidence-grading systems 
used by the organizations [2, 10-29]. 
3.3 Evidence-grading 
Recommendations included in guidelines are 
usually based on scientific and clinical evidence, 
which may result from clinical studies or experi-
ence. However, evidence may by be regarded as 
strong or less strong based on the kind of study it 
results from. Therefore, ranking/grading systems 
have been developed to rate the underlying evi-
dence of guidelines. As a rough and general refer-
ence scale, evidence may be ranked as follows: 
 
- High: large-scale clinical trials, randomized 
controlled trials (RCTs), meta-analyses of 
RCTs 
- Medium: non-randomized clinical studies 
with control group 
- Low: case series, clinical experience, expert 
opinion, and suggestions without verification 
in large clinical trials 
 
Table 1 also includes references to the grading 
systems that were used by the guideline providers 
to rate the underlying evidence on which their rec-
ommendations were based. However, it is impor-
tant to note that there are several rating systems, 
which use different scales and methods, and that 
the guideline-providing organizations have applied 
different systems. Thus, the ratings provided by 
the organizations are not easily comparable. 
3.4 Assessment of guideline relevance and evi-
dence used 
Once a guideline was assessed as being rele-
vant, the evidence presented was evaluated ac-
cording to the usual methodological requirements. 
Two experienced reviewers evaluated the guide-
lines independently. Data were extracted into evi-
dence tables by one reviewer (CF) and a second re-
viewer (AG) checked the extracted data. 
Keywords were derived from each guideline for 
further comparison. These keywords included: 
 
- Neuropathy (sensory, motor, autonomic) 
- Peripheral arterial disease 
- Foot deformation 
- Limited joint mobility 
- Patient foot care education 
- Multi-disciplinary diabetic foot care service 
- Adequate training for healthcare profession-
als 
- Self- monitoring/inspection of feet 
- Footwear provision and orthoses 
- Frequency of assessment/screening 
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Tables A1-A10 (in the Appendix) include the 
recommendation for each identified keyword for 
each organization, and the level of evidence that 
each guideline is based on, as reported by the or-
ganization, if this was available. 
4. Results 
We first evaluated whether recommendations 
for the different complications associated with the 
diabetic foot and relevant screening and care as-
pects are included in the guidelines. 
4.1 Evaluation of the completeness of guide-
lines 
The following aspects to be considered in diabe-
tes foot screening were included in all 10 guideline 
documents as part of the screening guideline (the 
tables that show the recommendations by each or-
ganization and the level of evidence on which the 
organization based the proposal are given in pa-
rentheses): 
- Peripheral neuropathy (Table A1) 
- Peripheral vascular disease (Table A2) 
- Inspection and provision of footwear (Table 
A3) 
- Foot deformation (Table A4) 
- Patient foot care education (Table A5) 
- Frequency of assessment and screening 
(Table A6) 
 
The following aspects of diabetes foot screening 
were not included in all 10 guideline documents: 
 
- Evaluation of limited joint mobility (Table 
A7) 
- Training for health care professionals (Ta-
ble A8) 
- Self-monitoring and inspection of feet by 
healthcare personnel (Table A9) 
- Multi-disciplinary team within a diabetic 
foot care service for the inspection of diabetic 
feet (Table A10) 
 
The findings indicate that the guidelines vary 
in their recommendations for screening, and more 
Table 2. Comparison of evidence-grading schemes 
 
Agency for Health Care Policy and Research (AHCPR) Scottish Intercollegiate Guidelines Network (SIGN) 
Level of evi-
dence 
Description Level of evi-
dence 
Description 
I Evidence obtained from a systematic review of 
all relevant randomized controlled trials. 
 
1++ High quality meta-analyses, systematic reviews 
of RCTs, or RCTs with a very low risk of bias 
II Evidence obtained from at least one properly-
designed randomized controlled trial. 
 
1+ Well conducted meta-analyses, systematic re-
views, or RCTs with a low risk of bias 
III-1 Evidence obtained from well-designed pseudo-
randomized controlled trials (alternate alloca-
tion or some other method). 
 
1- Meta-analyses, systematic reviews, or RCTs 
with a high risk of bias 
III-2 Evidence obtained from comparative studies 
(including systematic reviews of such studies) 
with concurrent controls and allocation not ran-
domized, cohort studies, case-control studies, or 
interrupted time series with a control group. 
2++ High quality systematic reviews of case control 
or cohort studies 
 
High quality case control or cohort studies with 
a very low risk of confounding or bias and a 
high probability that the relationship is causal 
 
III-3 Evidence obtained from comparative studies 
with historical control, two or more single arm 
studies, or interrupted time series without a 
parallel control group. 
 
2+ Well conducted case control or cohort studies 
with a low risk of confounding or bias and a 
moderate probability that the relationship is 
causal 
IV Evidence obtained from case series, either post-
test or pre-test/post-test. 
2- Case control or cohort studies with a high risk 
of confounding or bias and a significant risk that 
the relationship is not causal 
 
  3 Non-analytic studies, e.g. case reports, case se-
ries 
 
  4 Expert opinion 
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importantly, there is little or no evidence for some 
of the recommendations (see tables and section 
4.2). There are some agreements between the 
guidelines, but also clear differences. In particular, 
it is obvious that the quality of the underlying evi-
dence used to create the guidelines varies consid-
erably. While some guidelines used controlled tri-
als with or without randomization and/or meta-
analyses as evidence, others abstained from pro-
viding evidence completely. In this regard, it may 
be borne in mind that individuals who develop 
guidelines may employ different methodologies, 
and that the creation of a guideline may be influ-
enced by the aims, practices, and possibly ideas of 
the organization or professional body that has 
commissioned it. These are factors that may be re-
sponsible for the present differences. 
Another concern relates to the validity of the 
grading systems applied. The use of different grad-
ing systems, the disagreement between the guide-
lines regarding the grading of the evidence, and 
the different methods and scales of the grading 
systems make it difficult to compare the guidelines 
and to understand the recommendations [30]. 
The following two examples illustrate the dif-
ferences between the grading systems (Table 2): 
 
- The Scottish Intercollegiate Guidelines Net-
work (SIGN) rated evidence from 1++ (least 
likely to be biased) to 4 (greatest potential 
for bias), using a scale of 8 levels. Studies 
were assessed on the basis of critically ap-
praisal checklists. 
- The levels of evidence used by the Austra-
lian National Health and Medical Research 
Council (ANHMRC) were arranged so that 
they correspond to the methods and designs 
of the clinical studies. 
4.2 Qualitative evaluation of the guidelines – 
rating of evidence 
Peripheral neuropathy. Recommendations for the 
screening for peripheral neuropathy were included 
in all 10 foot screening guideline documents, as il-
lustrated in Table A1. Recommended screening 
tests included the 10 g monofilament test in com-
bination with vibration perception testing using a 
tuning fork or biothesiometer. However, although 
all guidelines highlighted the importance of 
screening for peripheral neuropathy to identify the 
insensate foot, the level of evidence, as assessed by 
the organizations themselves, supporting this rec-
ommendation differed considerably. Whilst some 
organizations such as the American Diabetes As-
sociation (ADA) graded this recommendation as 
grade B level of evidence [19], other organizations 
such as the Australian National Health and Medi-
cal Research Council (NHMRC) attached grades C 
or D to the same recommendation, advocating for 
caution when applying these recommendations 
[10]. This inconsistency is irritating since the aim 
of evidence-based guidelines is to improve the 
value of healthcare by recommending the best 
screening and treatment modalities to facilitate 
decision-making and improve care [31]. Inconsis-
tencies among systems for grading the quality of 
evidence and the strength of recommendations 
contribute to the degree of non-transparency, and 
reduce their potential to facilitate critical assess-
ment and improved application. 
 
Peripheral vascular disease. A guideline for the 
screening for peripheral vascular disease was also 
included in all 10 foot screening guideline docu-
ments, as shown in Table A2. All guidelines em-
phasized the importance of palpation of foot 
pulses, but the evidence grading for this recom-
mendation (provided by the organizations them-
selves) is poor in some guidelines. Some organiza-
tions such as the ADA assigned only grade C or D 
level of evidence [19], meaning that the supportive 
evidence is derived from poorly controlled or un-
controlled studies only, while other organizations 
such as the National Institute for Health and Care 
Excellence (NICE) gave an A rating [4], which 
means that the evidence is based directly on at 
least one RCT or a meta-analysis of RCTs. 
Clinicians need to be attentive to the validity of 
guidelines that claim to be evidence-based since 
some guidelines may contain information that has 
not been critically assessed for evidence quality 
[30]. Table A2 shows that some guidelines rely on 
expert opinion or clinical experience only (e.g. 
those from the Australian NHMRC, the Canadian 
Diabetes Association, the Institute for Clinical 
Systems Improvement, and the ADA) as random-
ized controlled trials were not available or unreli-
able because of the nature of the research con-
ducted to date. Guidelines that are based on either 
poorly controlled or non-controlled studies suggest 
that these recommendations should be adopted 
with caution due to the possibility of arterial calci-
fication, as shown in Table A2 (and discussed in 
more detail in the next paragraph). Other guide-
line providers, including the IDF and the New Zea-
land Guidelines Group, refer to evidence, but it is 
unclear how the recommendations were derived. 
Due to the deficit of information on a reliable 
method to screen for PAD in the high-risk foot new 
 164  The Review of DIABETIC STUDIES Formosa et al. 
   Vol. 13 ⋅ No. 2-3 ⋅ 2016 
 
Rev Diabet Stud (2016) 13:158-186  Copyright © by Lab & Life Press/SBDR 
structured studies and randomized control trials 
should be conducted to create sufficient evidence. 
Ankle-brachial pressure index (ABPI) is rec-
ommended as an additional test for the diagnosis 
of peripheral arterial disease in some of the guide-
lines analyzed. However, the evidence for this rec-
ommendation is controversial. A recent clinical 
study conducted by our group demonstrated the 
limitations of ABPI as a diagnosis tool in periph-
eral arterial disease (PAD) and patients with dia-
betes mellitus [32]. ABPI thresholds of less than 
0.9 and more than 1.3 are highly suggestive of 
PAD. However, when there is concomitant clinical 
peripheral neuropathy or a high risk of arterial 
calcification (Monckberg’s sclerosis), the efficiency 
of ABPI is limited because a falsely elevated ABPI 
may be generated. Based on these new findings, it 
is recommended that peripheral arterial disease in 
people with diabetes should be assessed using both 
ABPI and Doppler waveform in combination. 
When the findings from both test modalities do not 
correlate, then subjects should be monitored or the 
examination continued. Additional physiological 
testing could include toe pressure and toe brachial 
pressure indices to determine whether PAD is ac-
tually present. Despite the evidence that Doppler 
waveform is an important additional test modality 
for the diagnosis of PAD as ABPI may give false 
values in calcified arteries, the 10 guidelines ana-
lyzed do not refer to Doppler waveform analysis. 
 
Inspection and provision of footwear. Recommen-
dations for the inspection and provision of foot-
wear were included in all 10 foot screening guide-
line documents, as illustrated in Table A3. How-
ever, the evidence on the importance of inspection 
and provision of footwear in the guidelines varies 
considerably. This issue has also been analyzed by 
Healy et al., indicating that no research has exam-
ined the effectiveness of footwear in preventing ul-
ceration to date [33]. The authors also reported 
conflicting findings on the effectiveness of footwear 
interventions to prevent re-ulceration, and rec-
ommended that further studies were performed to 
explore the type of therapeutic footwear required 
to reduce ulceration in patients with neuropathy 
and deformities. It is striking that only 1 of the 10 
guidelines analyzed included acceptable evidence 
on the effectiveness of footwear interventions to 
prevent ulceration (CDA) [11]. Two cited rather old 
studies from the 90s only (NICE and SIGN) [4, 16], 
4 referred to other guidelines or a single review ar-
ticle only (NHMRC, ADA, IWGDF, IDF) [10, 19-21, 
29], and 3 included no evidence at all (DDG, 
ICFSI, NZSSD) [14, 17]. This shows that the 
guidelines lack sufficient evidence. Given this 
situation, it is impossible to identify an appropri-
ate recommendation that warrants adoption in 
clinical practice. It is necessary that more ade-
quately powered research is conducted on the in-
spection and provision of therapeutic footwear to 
safeguard the high-risk foot. Given the advances in 
material science and measurement techniques, 
such studies could employ quantitative outcome 
measures that are reliable and repeatable. 
 
Limited joint mobility and foot deformations. Rec-
ommendations for the inspection of limited joint 
mobility and foot deformities in patients living 
with diabetes did not form part of the screening 
guidelines included in all the 10 foot screening 
guideline documents (Table A4). Studies have re-
ported that foot morphology and foot deformations 
have been associated with ulcer development [34]. 
It is known that even slight pressure over a fixed 
bony deformation such as a prominent metatarsal 
head or a hammer toe can lead to necrosis and ul-
ceration of the skin. However, the clinical guide-
lines lack sufficient evidence on these problems 
and provide poor information. Those guidelines 
that do include a recommendation for the evalua-
tion of existing foot deformations support their 
recommendations with by low-quality evidence 
that is not based on well-defined or well-conducted 
studies (i.e. poorly controlled or uncontrolled stud-
ies, case reports, clinical experience, or expert 
opinion). 
There has been technological and scientific pro-
gress relating to the clinical assessment and inter-
vention of foot deformities, including wearable 
sensors and advanced materials with an option of 
3D printing, which should be reflected in the 
guidelines. However, such changes in guidelines 
can happen only if enough clinically acceptable 
evidence through structured investigations is 
available. We recommend that potential guidelines 
should compile and make use of existing experi-
mental evidence rather than anecdotal and opin-
ion-based evidence. 
The current state of research to date in this 
area does not allow robust recommendations to be 
made for the screening of limited joint mobility, 
which is due to the lack of randomized controlled 
trials. Well-designed studies need to be carried out 
to provide strong evidence in this area. Foot mor-
phology and foot deformity have been previously 
identified in other studies as potential risks of ul-
ceration [34]. Thus, healthcare professionals need 
to inspect and evaluate these deformations sys-
tematically both before and after ulcers occur to 
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prevent recurrence, especially in countries with a 
high rate of amputations. Such systematical in-
spection is possible only if reliable guidelines are 
available, and this in turn requires the perform-
ance of well-designed studies to provide the neces-
sary evidence as basis for optimal healthcare. 
Studies highlight the importance of increased at-
tention on part of the clinical personnel coupled 
with the intensification of existing screening ef-
forts and introduction of reliable clinical guidelines 
including the biomechanical assessment of the feet 
[35]. These efforts could reduce the incidence of 
diabetic foot complications, but we are still far 
from realizing them. This problem is reflected by 
the existing guidelines and the limited or lacking 
evidence needed to justify them. As shown in Ta-
ble A4, most guidelines are based on poorly con-
trolled or non-controlled studies. For example, the 
Australian NHMRC graded the evidence as C, 
which is described as evidence that provides some 
support for the recommendation, but not enough to 
apply the recommendation without further obser-
vation and caution. 
 
Patient foot care education. A recommendation ad-
vocating the importance of patient foot care educa-
tion for patients living with diabetes as part of the 
screening guidelines was included in all 10 foot 
screening guideline documents, as shown in Table 
A5. Although all guidelines emphasize the impor-
tance of foot care education, they fail to identify 
the best methodological approach, making it diffi-
cult for guideline users to adopt this recommenda-
tion. Previous studies have reported conflicting re-
sults regarding outcomes of diabetes education 
programs [36]. It is known that improving knowl-
edge alone is not sufficient to improve adherence 
to treatment and care regimens that involve be-
havioral change, although a few studies have 
shown that diabetes education programs produce 
statistically significant health benefits, at least in 
the short-term. 
Patient education activities are currently im-
plemented in various ways in different countries. 
Most countries use didactic education primarily, 
but remain at an experimental stage as far as the 
different ways of developing patient education are 
concerned [37]. Diabetes education is often pre-
scriptive, offered on an ad hoc basis, and is not 
continuous so that the patient is not provided with 
new knowledge on a timely basis. It is even more 
problematic that current education programs are 
not based on scientifically proven educational or 
behavioral principles that may result in better 
outcomes [38]. These problems limit the effective-
ness of such programs considerably. Therefore, 
well-conducted, generalizable RCTs are necessary 
to explore new psychosocial intervention strategies 
in diabetes care for preventing diabetic foot ulcera-
tions and amputations. 
A general reconsideration of the traditional 
biomedical model of care is necessary to develop a 
biopsychosocial model. This may be the first step 
in achieving a positive change. Other recommen-
dations included in some of the guidelines advo-
cated the “importance of self-monitoring and in-
spection of feet” and “the importance of having a 
multi-disciplinary foot care service”. However, the 
organizations provided these two important rec-
ommendations by using different levels of evi-
dence. While NICE attached grade ‘A’ level of evi-
dence to their recommendation, and provided evi-
dence directly based on meta-analysis of RCTs [4], 
the Australian NHMRC based their recommenda-
tion on expert opinion only [10]. This discrepancy 
is mirrored by the inconsistency of the evidence on 
educational programs for the prevention of ulcer 
recurrence and amputation, suggesting that more 
research is necessary on this issue. 
 
Frequency of assessment/screening. A recommen-
dation regarding the frequency of assessing and 
screening patients living with diabetes by both pa-
tients and healthcare professionals as part of the 
screening guidelines was included in all 10 foot 
screening guideline documents, as shown in Table 
A6. Although all guidelines analyzed uniformly 
emphasized the importance and frequency of as-
sessing and screening people living with type 2 
diabetes, the evidence provided in support of this 
recommendation was of poor quality. 
More attention should be paid to the limitations 
of the guidelines and underlying evidence from 
which they were devised as this might be the rea-
son for the current gap between recommendation 
and practice. An evidence-grading system based on 
relevant populations, patient-oriented outcomes, 
and shared decision-making could improve physi-
cian information and patient guideline adherence, 
and thus improve diabetes foot screening outcomes 
[31]. Furthermore, new structured research with 
appropriately designed trials needs to be con-
ducted to remedy the lack of evidence. These ef-
forts could be of great benefit to the increasing 
number of people with and at risk of type 2 diabe-
tes and its complications. 
5. Discussion 
The aim of this study was to evaluate critically 
the guidelines currently adopted by different or-
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ganizations to facilitate foot screening in patients 
with diabetes, with a view to providing ways of 
improving existing screening methods, which could 
save limbs. Given the dynamic nature of the re-
search into this topic, the WHO emphasized the 
need for new evidence from randomized controlled 
trials and observational studies to evaluate and 
improve the screening for diabetes [39]. However, 
to date, such new research and screening efforts 
have not been achieved in the area of the diabetic 
foot, in contrast to screening for several other 
chronic conditions, e.g. various types of cancers. 
The overall goal of screening guidelines is to 
prevent diabetic foot complications or at least to 
halt or decelerate their development. This requires 
that the feet diabetes patients are inspected regu-
larly and treated by skilled healthcare profession-
als. However, our evaluation of the existing diabe-
tes foot screening guidelines revealed huge vari-
ability in the recommended methods and conflict-
ing or missing evidence on which the recommenda-
tions were based. Also, the guidelines used differ-
ent grading systems to grade their recommenda-
tions, making it difficult to compare the guidelines. 
It is inappropriate to publish recommendations 
that are not based on any scientific evidence, 
which is the case with some of the guidelines ana-
lyzed, as discussed above. Diabetic foot complica-
tions are increasing at alarming rates. Therefore, 
looking at endocrine functions and treatment pro-
cedures alone is not sufficient to stop the trend. 
The literature advocates for more prevention [39]. 
However, preventive measures are sometimes im-
practical and corresponding recommendations lack 
robust evidence [40, 41]. 
Since the 1970s, different organizations have 
employed various systems to grade the quality 
(level) of evidence and the strength of their rec-
ommendations. Unfortunately, organizations use 
different systems to grade evidence and recom-
mendations. The same evidence and recommenda-
tion could be graded as II-2, B, C+, 1, “strong evi-
dence”, or “strongly recommended” depending on 
the system used. This is confusing and impedes ef-
fective communication [30]. Furthermore, it has 
been reported that most of the currently used ap-
proaches to grade evidence and the strength of 
recommendations have important shortcomings. 
This diversity makes comparisons and syntheses 
of findings difficult. 
Our findings show that guidelines are inconsis-
tent in how they rate quality of evidence and grade 
strength of recommendations. As a result, guide-
line users may be irritated and find it difficult to 
understand the messages that rating systems are 
trying to communicate. Evidence rating systems 
are included in most foot screening guidelines. 
They aim to establish a hierarchy of evidence that 
usually acknowledges the primacy of randomized 
controlled trials, followed by observational studies, 
and expert opinion when sufficiently sound evi-
dence on a particular issue is not available. How-
ever, some guidelines contain considerable mate-
rial that has not been critically assessed for evi-
dence quality or reference to evidence has not been 
provided by the guideline publishers. Such guide-
lines rely on expert consensus or non-randomized 
clinical experience only (see Tables A1-A10). Most 
of these guidelines have not used rigorously the 
guideline methodologies for identification and 
analysis of evidence. Those which lack sufficient 
evidence behind their recommendations should be 
revised thoroughly by adjusting the recommenda-
tions and using the latest and most robust re-
search findings. New evidence should be created 
where recommendations are needed to achieve bet-
ter clinical outcomes (such as reduction in ulcera-
tions and amputations, and improved quality of 
life), but findings from well-conducted studies are 
missing (such as for screening for neuropathy and 
peripheral artery disease, inspection and provision 
of footwear, and inspection of foot deformations). 
The revision of guidelines should be carried out in 
such a way that inconsistencies are reduced and 
new evidence is included, while the evidence 
should be carefully analyzed regarding study type, 
quality, and relevance of the findings both clinical 
and for the target population [2]. 
It is therefore suggested that more attention 
should be paid to the limitations of these guide-
lines and the underlying evidence on the basis of 
which they were devised as this may be one reason 
for the current gap between recommendation and 
standard practice. In this regard, special attention 
should be given to the evaluation of foot biome-
chanics, training of healthcare professionals, self-
monitoring, and the importance of a multidiscipli-
nary team approach, as highlighted in Tables A7-
A10, since these aspects of diabetes foot screening 
were not included in all 10 guidelines analyzed in 
this article. With advances in technology, model-
ing, and other treatment innovations, refining cur-
rent foot screening guidelines could preserve func-
tional limbs in high-risk patients. 
6. Conclusions and recommendations 
This study highlighted that the current guide-
lines lack evidence in one or more of their recom-
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mendations. As the global prevalence of diabetes is 
increasing because of population growth, ageing of 
populations, and lifestyle changes associated with 
urbanization screening guidelines need to include 
the latest advances in clinical management. 
Proper screening and management in the preven-
tion of diabetes complications is essential. Whilst 
the recommendations included in the guidelines 
are mostly similar, there are substantial differ-
ences in the grading of these recommendations. Al-
though this may not impact policy development 
and implementation of recommendations in a spe-
cific setting, it is necessary to include current de-
velopments in science and information technology 
when revising the guidelines. It should be ac-
knowledged that there could be practical reasons 
for the differences in the guidelines for screening 
procedures, depending on what is possible and 
available in a particular country. 
Based on the results, future research in diabe-
tes foot screening should also be oriented to the 
needs of physicians and patients to improve 
healthcare. Furthermore, large-scale, randomized 
trials are needed to demonstrate convincingly the 
benefit of various foot screening recommendations 
and improve outcomes. Detailed information re-
garding the sources of the evidence used in each 
guideline should be clearly reported within the 
guidelines. This will enable new guideline devel-
opers to refer to the work performed and published 
by others as ‘source’ guidelines, and to optimize 
and standardize diabetes foot screening guidelines. 
It will also be important that guidelines are 
more explicit and accurate so that recommenda-
tions are addressed clearly to facilitate adoption, 
adherence, and improve outcomes. When formulat-
ing screening guidelines, the aim of any screening 
policy should be clearly stated. Epidemiological 
considerations, issues of health system capacity, 
economic considerations, the assessment of tests 
taking into account sensitivity and specificity, 
competing priorities, and ethical and political con-
siderations need to be considered and clearly 
stated [39]. Evidence needs to be reviewed on a 
regularly basis as new evidence accumulates. A 
paradigm shift on how to screen for risk factors in 
the high-risk population using high-quality evi-
dence is urgently needed should the risks of foot 
ulceration and its devastating consequences be re-
duced. 
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Table A1. Peripheral neuropathy screening recommendations included in the guidelines analyzed 
 
Guideline Recommendation Grading of evidence, as provided by the guideline pub-
lisher 
National Health and 
Medical Research Coun-
cil (Australia), 2011 
 
Neuropathy disability score: ankle (Achil-
les) reflexes and the sensory modalities of 
pinprick, vibration and temperature percep-
tion 
 
Vibration perception: using tuning fork, 
biothesiometer or  
10 g monofilament sensitivity 
 
Evidence-based recommendation set up according to a system-
atic review of the literature. Grade C using the NHMRC grad-
ing system. The body of evidence provides some support for 
these recommendations (Boulton 2005 [42], Leese et al. 2006 
[43]), but recommendation should be applied with caution. 
Canadian Diabetes Asso-
ciation (Canada), 2013 
Evaluation of neuropathy: 10 g monofila-
ment over the distal plantar surface of the 
foot 
Grade D, level 4, using CDA system. Evidence cited: Boulton et 
al. 2008 [8], Feng et al. 2011 [44] 
Evidence should meet 1 or 2 of the following criteria: 
a) Independent interpretation of test results (without knowl-
edge of the result of the diagnostic or gold standard) 
b) Independent interpretation of the diagnostic standard 
c) Selection of people suspected to have the disorder 
d) Reproducible description of both the test and diagnostic 
standard 
e) At least 50 patients with and 50 patients without the disorder 
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Table A1 continued 
 
Guideline Recommendation Grading of evidence, as provided by the guideline pub-
lisher 
National Institute for 
Clinical Excellence, Eng-
land and Wales (NICE), 
2014 
Testing of foot sensation using 10 g mono-
filament (changed every 10 patients in one 
session and left for at least 24 hr to recover 
buckling strength) or vibration using bio-
thesiometer or calibrated tuning fork. 
Foot sensation: grade C (evidence from non-experimental de-
scriptive studies or extrapolated recommendation from meta-
analysis of RCTs or at least one RCT), but no reference to evi-
dence was given by the guideline publisher. 
Vibration: grade A, III (evidence from meta-analysis of RCTs or 
from at least one RCT), but no reference to evidence was given 
by the guideline publisher. 
 
Deutsche Diabetes Ge-
sellschaft (Germany), 
2014 
10 g monofilament (for foot sensation) 
and/or vibration testing using a Rydell-
Sieffer tuning fork. 
 
No grading and no evidence provided. 
Scottish Intercollegiate 
Guidelines Network 
(Scotland), 2013 
10 g monofilament, neuropathy disability 
score. A neurothesiometer can be used as 
part of a more formal assessment. 
Grade 2++ (evidence results from findings from a study of 
strong design, but with some uncertainty because of inconsis-
tent results or other issues). Relevant citation: Abbott et al., 
2002 [45]. 
 
Institute for Clinical Sys-
tems Improvement, 
(USA), 2014  
 
Assessed by 5.07 Semmes-Weinstein mono-
filament or by testing vibration using 128-Hz 
tuning fork at the dorsum of the interpha-
langeal joint of the great toe to detect loss of 
protective sensation. 
 
Low-quality evidence (the guideline publisher indicated that 
further research is very likely to have an important impact on 
the confidence in the estimate of the effect). No reference to 
evidence provided by the guideline publisher. 
American Diabetes Asso-
ciation (USA) 2014 
10 g monofilament plus any of the following: 
vibration using 12-Hz tuning fork, pinprick 
sensation, ankles reflexes, vibration percep-
tion threshold. 
 
Grade B (only supportive evidence from well-conducted cohort 
studies). No reference to evidence given for this recommenda-
tion; only cited Boulton et al., 2008 [8], but not next to the rec-
ommendation. 
International Working 
Group on the Diabetic 
Foot, 2015 
Examine the feet annually to look for symp-
toms of peripheral neuropathy. 
 
Sensory loss due to diabetic polyneuropathy 
should be assessed using the following tech-
niques: 10 g monofilament (pressure percep-
tion), 128 Hz tuning fork (vibration), pin 
prick and tactile sensation (discrimination), 
cotton wool on dorsum of the foot (sensa-
tion), and Achilles tendon reflexes (re-
flexes). 
 
GRADE recommendation: strong. Quality of evidence: low (no 
reference to evidence provided). 
 
No specific evidence or grading provided for this recommenda-
tion. Note: evidence provided in the guideline paper (Bakker et 
al., 2012 [21]) but not clearly assigned to the recommendation. 
Articles cited in the guideline paper have been regarded as the 
evidence, which has been assessed according to the ‘QUADAS 
tool’, and graded according to the GRADE system. However, 
grades are not provided for all recommendations). 
International Diabetes 
Federation, 2012 (up-
dated 2015) 
 
Detection of neuropathy by 10 g monofila-
ment (or 128 Hz tuning fork). Biothesiome-
ter as option for quantitative assessment 
(cut-off point for risk of ulcer > 25 volts). 
Non-traumatic pin-prick test. 
 
Evidence-based, but unclear from where the recommendations 
were derived. Cited are only other guidelines: NHMRC 2011 
[9], SIGN 2013 [16], Bakker et al. 2012 [21], ADA 2014 [19], 
NICE 2014 [12], CDA 2013 [11] (partly newer versions of the 
papers). 
New Zealand Society for 
the Study of Diabetes 
(NZSSD) - Podiatry Spe-
cial Interest Group, 2014 
Neuropathy screening using 10 g monofila-
ment, vibration test using 128 Hz tuning 
fork, perception thresholds using a biothe-
siometer. 
 
Grade C (low-quality observational studies or extrapolated evi-
dence). No reference to evidence provided by the guideline 
publisher. 
 
Legend: GRADE - Grading of Recommendations Assessment, Development, and Evaluation, QUADAS – Quality Assessment Tool for Dia-
gnostic Accuracy Studies. 
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Table A2. Peripheral artery screening recommendations included in the guidelines analyzed 
 
Guideline provider Recommendation Grading of evidence, as provided by the guideline pub-
lisher 
National Health and 
Medical Research Coun-
cil (Australia), 2011 
 
Palpation of peripheral foot pulses 
 
 
 
 
 
Ankle brachial pressure index (ABPI) using 
Doppler ultrasound recommended as useful 
adjunct to assess arterial perfusion of the foot. 
Can be falsely elevated in the presence of ar-
terial calcification. The toe-brachial pressure 
index or toe pressures are useful adjuncts for 
assessing arterial perfusion of the foot if the 
ABPI is falsely elevated. 
 
Evidence-based recommendation set up according to a system-
atic review of the literature. Grade C. Body of evidence provides 
some support for the recommendation, but should be applied 
with caution. Cited: McCabe et al., 1998 [46]. 
 
Evidence from a systematic review and expert opinions in the 
absence of evidence. Cited: Abott et al. 2002 [45]; Pham et al. 
2000 [47]; Leese et al. 2006 [43]. 
Canadian Diabetes Asso-
ciation (Canada), 2013 
 
Palpation of foot pulses 
 
 
ABPI useful adjunct to assess arterial perfu-
sion of the foot 
+ Determination of systolic toe pressures by 
photoplethysmography (PPG), transcutane-
ous oxygen (TCPO2), and spectral Doppler 
waveform analysis. 
 
Grade D, level 4 (for description see Table A1). Cited: Kalani et 
al. 1999 [48], Faglia et al. 2005 [49]  
 
Grade D, level 4. Kalani et al. 1999 [48], Faglia et al. 2005 [49] 
National Institute for 
Clinical Excellence, Eng-
land and Wales (NICE), 
2014 
Palpation of foot pulses 
 
 
 
Patients who may benefit from re-
vascularization should be referred promptly. 
 
Grade A (from meta-analysis of RCTs or from at least one RCT). 
However, no reference to evidence is provided by the guideline 
publisher for this recommendation. 
 
Grade D (from expert committee reports, opinions and/or 
clinical experience). However, no reference to evidence is pro-
vided by the guideline publisher for this recommendation. 
 
Deutsche Diabetes Ge-
sellschaft (Germany), 
2014 
 
- Foot Pulses 
- Measurement of arterial occlusion pressure 
over the dorsalis pedis and tibial posterior 
arteries 
- Determination of the ABPI 
 
No grading and no evidence provided. 
Scottish Intercollegiate 
Guidelines Network 
(Scotland), 2013 
 
Palpation of pulses using Doppler ultrasound. 
ABPI can be used to assess PAD. 
 
 
All patients with critical limb ischemia, in-
cluding rest pain, ulceration, and tissue loss, 
should be considered for arterial reconstruc-
tion. 
 
Grade 2++. Evidence consisting of results from studies of strong 
design, but with some uncertainty regarding the results. 
 
Grade B, 2++ 
Institute for Clinical Sys-
tems Improvement 
(USA), 2014  
Pedal pulses, record history of claudication, 
or ischemic skin changes 
 
Consider obtaining an ABPI if clinically indi-
cated. PAD slowed by smoking cessation and 
treatment of hypertension and dyslipidmia. 
Consider referral of patients with claudication 
and/or absent pedal pulses for vascular sur-
gery. 
 
Low-quality evidence.  No reference to evidence is provided by 
the guideline publisher. 
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Table A2 continued 
 
Guideline provider Recommendation Grading of evidence, as provided by the guideline pub-
lisher 
American Diabetes Asso-
ciation (USA), 2014 
Assessment of foot pulses, dorsalis pedis, 
and posterior tibial characterized as present 
or absent. 
 
Inclusion of initial screening for peripheral 
artery disease (PAD), history for claudica-
tion, and assessment of pedal pulses. Obtain 
ABPI. In presence of incompressible calf or 
ankle arteries, toe pressure or transcutane-
ous oxygen tension may be performed. 
 
Initial screening for PAD should include a 
history of claudication and an assessment of 
pedal pulses. A diagnostic ankle-brachial in-
dex (ABI) system should be used in any pa-
tient with symptoms of PAD. Due to the 
highly estimated prevalence of PAD in pa-
tients with diabetes, and the fact that many 
patients with PAD are asymptomatic, an ADA 
consensus statement on PAD [47] suggested 
that a screening ABI should be performed in 
patients over 50 years of age, and be consid-
ered in patients under 50 years of age who 
have other PAD risk factors (e.g., smoking, 
hypertension, hyperlipidemia, or duration of 
diabetes >10 years). Refer patients with sig-
nificant symptoms or a positive ABI for fur-
ther vascular assessment and consider exer-
cise, medications, and surgical options. 
 
Grade C. Cited: ADA, 2003 [50] (part of guideline)  
 
 
Grade C. Cited: ADA, 2003 [50] (part of guideline) 
 
 
 
 
 
Grade C. Cited: ADA, 2003 [50] (part of guideline) 
 
 
 
 
 
 
International Working 
Group on the Diabetic 
Foot, 2015 
Examine the feet annually to look for symp-
toms of peripheral artery disease. 
 
Pedal pulses, claudication, rest pain. In pa-
tients with ABPI of <0.6, toe pressures <50 
mmHg, or TCPO2 <30 mmHg revasculariza-
tion should be considered. 
 
GRADE recommendation: strong. Quality of evidence: low (no 
reference to evidence provided). 
 
No specific evidence or grading provided for this recommen-
dation (see Table A1). 
International Diabetes 
Federation, 2012 (updated 
2015) 
 
Palpation of foot pulses (dorsalis pedis and 
posterior tibial). Doppler ankle/brachial 
pressure ratio (< 0.9 for occlusive vascular 
disease) may be used where pulses are di-
minished to quantify the abnormality. 
 
Evidence-based, but unclear from where recommendations 
were derived, obviously collected from other guidelines. 
Cited are other guidelines: NHMRC 2011 [9], SIGN 2013 [16], 
Bakker et al. 2012 [21], ADA 2014 [19], NICE 2014 [12], CDA 
2013 [11] (partly newer versions). 
New Zealand Society for 
the Study of Diabetes 
(NZSSD) - Podiatry Special 
Interest Group, 2014 
Assessment of peripheral circulation through 
evaluation of symptomatic claudication 
and/or rest pain, and palpation of pedal 
pulses. 
 
It is not known from where this guideline was derived. No 
grading and no evidence provided. 
 
Legend: ABI – ankle-brachial index, ABPI – ankle brachial pressure index, PAD – peripheral artery disease, PPG – photoplethysmography, 
TCPO2 – transcutaneous oxygen. 
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Table A3. Inspection and provision of footwear screening guidelines 
 
Guideline provider Recommendation Grading of evidence, as provided by the guideline 
publisher 
National Health and 
Medical Research Coun-
cil (Australia), 2011 
 
Appropriate footwear and hosiery 
 
 
 
 
 
Therapeutic footwear 
Grade C. Cited: McCabe et al., 1998 [46]. Evidence-based 
recommendation set up according to a systematic review of 
the literature. A body of evidence provides some support 
for the recommendation, but should be applied with cau-
tion. 
 
Two average quality trials (not referenced in the guideline 
paper next to the recommendation). Insufficient evidence 
to determine the effectiveness of therapeutic footwear. 
 
Canadian Diabetes Asso-
ciation (Canada), 2013 
 
People at high risk of foot ulceration or amputa-
tion should have professionally fitted therapeutic 
footwear. 
Grade C, level 3.  
Meets 3 of the following criteria: 
a) Independent interpretation of test results. 
b) Independent interpretation of the diagnostic standard, 
c) Selection of people suspected to have the disorder, 
d) Reproducible description of both the test and diagnostic 
standard, 
e) At least 50 patients with and 50 patients without the dis-
order. 
Cited: Bus et al., 2008 [51]; Arad et al., 2011 [52], Valk et 
al., 2002 [53], McCabe et al., 1998 [46]. 
 
National Institute for 
Clinical Excellence, Eng-
land and Wales (NICE), 
2014 
Inspection of footwear 
 
 
 
In people with diabetes and previous ulceration, 
footwear should be inspected at each examina-
tion, specialist footwear and insoles should be 
provided. However, the guideline indicates that 
there is conflicting evidence about the impact of 
therapeutic footwear on the risk of further ulcera-
tion. 
 
Grade A (from meta-analysis of RCTs or from at least one 
RCT). 
 
 
Grade 1b (evidence obtained from at least one 
well-designed quasi- experimental study). 
 
Cited (rather old articles): Colagiuri et al., 1995 [54]; Lit-
zelman et al., 1997 [55]; McCabe et al., 1998 [46]; Reiber et 
al., 2002 [56]; Uccioli et al., 1995 [57].  
Deutsche Diabetes Ge-
sellschaft (Germany), 
2014 
Footwear of all diabetics should be examined pe-
riodically. 
Footwear provision according to risk class. 
 
No grading provided. 
Scottish Intercollegiate 
Guidelines Network 
(Scotland), 2013 
 
Preventative footwear and orthoses. Patients with 
diabetic foot disease should be advised to wear 
running-style, cushion-soled trainers rather than 
ordinary shoes.  
 
 
 
Custom-built footwear or orthotic insoles should 
be used to reduce callus severity and ulcer recur-
rence.  
 
Patients who routinely wear their prescription 
shoes and orthoses are less likely to have ulcer 
relapse. 
 
Grade B (high-quality case-control or cohort studies with a 
very low risk of bias or extrapolated evidence from high-
quality meta-analyses, systematic reviews of RCTs, or RCTs 
with a very low risk of bias). Cited: (rather old articles): 
Colagiuri et al., 1995 [54], Edmonds et al., 1986 [58], Uc-
cioli et al., (1995) [57]. 
 
Grade B. Cited: Dargis et al., 1999 [59]. 
 
 
 
Grade 3 (defined as non-analytic study, e.g. case report, 
case series). Cited: Breuer, 1994 [60]. 
Institute for Clinical Sys-
tems Improvement 
(USA), 2014 
 
Inspection of footwear for excessively worn, ill 
fitting, or inappropriate shoes. 
Low-quality evidence. No reference to evidence provided by 
guideline publisher. 
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Table A3 continued 
 
Guideline provider Recommendation Grading of evidence, as provided by the guideline 
publisher 
American Diabetes Asso-
ciation (USA), 2014 
People with neuropathy or evidence of increased 
plantar pressure (e.g., erythema, warmth, callus, 
or measured pressure) may be adequately man-
aged with well-fitted walking shoes or athletic 
shoes that cushion the feet and redistribute pres-
sure. Callus can be debrided with a scalpel by a 
foot care specialist or other health professional 
with experience and training in foot care. 
 
People with bony deformities (e.g., hammertoes, 
prominent metatarsal heads, bunions) may need 
extra-wide or -deep shoes. People with extreme 
bony deformities (e.g., Charcot foot) who cannot 
be accommodated with commercial therapeutic 
footwear may need custom-molded shoes. 
 
No grading and no evidence provided. Cited: Boulton et al., 
2008 [8] (part of guideline). 
International Working 
Group on the Diabetic 
Foot, 2015 
 
Appropriate footwear both indoor and outdoor 
should be used to accommodate the altered bio-
mechanics and deformities. Plantar pressure re-
duction can be achieved with footwear that in-
cludes a molded insole, although the amount of 
reduction is not certain. 
 
Patients without loss of protective sensation can 
select off-the-shelf footwear. Patients with neu-
ropathy and/or ischemia need extra care for fit-
ting footwear, in particular when deformities are 
present [49] 
 
Insole material and soft padding alone do not 
seem to have a great effect on plantar pressure, 
although some studies have found significant dif-
ferences. 
 
No grading provided for this recommendation. Cited: Bus 
et al., 2008 [51] (other guideline paper only, no evidence). 
 
 
 
 
 
See above. 
 
 
 
 
 
See above 
International Diabetes 
Federation, 2012 (up-
dated 2015) 
 
Evaluate footwear: provide advice, specialist in-
soles, and shoes if indicated in the high-risk dia-
betic foot. 
Evidence-based, but unclear from where recommendations 
were derived. Cited are only other guidelines (no evi-
dence): NHMRC 2011 [9], SIGN 2013 [16], Bakker et al., 
2012 [21], ADA 2014 [19], NICE 2014 [12], CDA 2013 [11]. 
 
New Zealand Society for 
the Study of Diabetes 
(NZSSD) - Podiatry Spe-
cial Interest Group, 2014 
People with diabetic foot disease should be ad-
vised to wear high-quality, cushioned running or 
sports shoes rather than ordinary shoes. 
 
People with high-risk feet, deformation, or previ-
ous amputation, should use custom-built footwear 
or orthotic insoles to reduce callus severity and 
ulcer recurrence. 
 
Grade B (well-designed observational studies or extrapo-
lated evidence from RCTs). It is not known from where this 
recommendation was derived. 
 
Grade B. It is not known from where this recommendation 
was derived. No reference to evidence provided. 
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Table A4. Foot deformation guidelines 
 
Guideline Recommendation Grading of evidence, as provided by the guideline 
publisher 
National Health and 
Medical Research Coun-
cil (Australia), 2011 
 
Use of the “Foot Deformity Score” to assess foot 
deformation.  This includes, but is not limited to 
the following conditions: hallux deformity, ham-
mer/claw toe, callus, previous amputations, ex-
cessively flat or high-arched feet, abnormally 
wide feet, and Charcot’s neuroarthropathy. 
 
Evidence-based recommendation set up according to a sys-
tematic review of the literature. Grade C using the NHMRC 
grading system. The body of evidence provides some sup-
port for these recommendations, but should be applied with 
caution (Pham et al., 2000 [47]; Abott et al., 2002 [45]; Boul-
ton, 2005 [42]; Leese et al. 2006 [43]). 
Canadian Diabetes Asso-
ciation (Canada), 2013 
Assessment by healthcare providers should in-
clude assessment of bony foot deformations. 
 
Grade D, level 4 (for description see Table A1). Cited: Boul-
ton et al., 2008 [8]. 
NICE, 2014 Inspection and assessment of any foot deforma-
tion. 
 
Grade 1b. Evidence derived from at least one RCT (Pham et 
al., 2000 [47]). 
Deutsche Diabetes Ge-
sellschaft (Germany), 
2014 
 
Examination of both feet for foot deformations. No grading and no evidence provided. 
Scottish Intercollegiate 
Guidelines Network 
(Scotland), 2013 
Simple tests to assess the presence of significant 
structural abnormalities. 
Grade 2++ (evidence from a study of strong design, but 
with some uncertainty because of inconsistent results or 
other issues). Relevant citation: Abbott et al., 2002 [45]. 
 
Institute for Clinical Sys-
tems Improvement 
(USA), 2014  
 
A foot examination should include an assessment 
of structural deformations such as bunions, 
hammer toes, Charcot deformity, and prior ampu-
tation. 
 
Guideline publisher indicated low-quality evidence, but 
provided no reference to evidence. 
American Diabetes Asso-
ciation (USA), 2014 
Common foot deformations are known to increase 
plantar pressure, and are associated with skin 
breakdown or amputations. Therefore, they need 
to be recorded during the screening process. 
 
Grade B. Cited: Boulton et al., 2008 [8]. 
International Working 
Group on the Diabetic 
Foot, 2015 
Deformations, including claw toes, hammer toes, 
or bony prominences, should be recorded during 
history taking. 
 
No specific evidence or grading provided for this recom-
mendation (see Table A1). 
International Diabetes 
Federation, 2012 
Assessment of foot deformation, including ham-
mer toes, clawed toes, and bone prominences. 
 
No grading provided. Cited other guideline: ADA, 2014 
[19]. 
New Zealand Society for 
the Study of Diabetes 
(NZSSD) - Podiatry Spe-
cial Interest Group, 2014 
 
Identify and manage foot deformations. Signifi-
cant structural foot deformations should be 
marked as present or absent. 
No grading of evidence provided. Cited: Litzelman et al., 
1997 [61]; Rith-Najarian et al., 1992 [62]; Klenerman et al., 
1996 [63]. 
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Table A5. Patient foot care education guidelines 
 
Guideline Recommendation Grading of evidence, as provided by the guide-
line publisher 
National Health and Medical 
Research Council (Australia), 
2011 
 
Foot care education should be provided to all peo-
ple with diabetes to assist in the prevention of foot 
complications. 
Expert opinion used to derive the recommendation, 
because of the inconsistent nature of the currently 
available evidence on educational programs for the 
prevention of ulcer recurrence and amputation. No 
reference to evidence provided. 
 
Canadian Diabetes Association 
(Canada), 2013 
 
People at high risk of foot ulceration and amputa-
tion should receive foot care education. 
Grade C, level 3 (see Table A3). Cited: Arad et al., 
2011 [52]; Valk et al., 2002 [53]; McCabe et al., 1998 
[46]. 
NICE, 2014 Offer patient education on an ongoing basis. 
 
 
 
Use of different patient education approaches until 
optimal methods available. 
Grade A (directly based on evidence from meta-
analysis of randomized controlled trials; reference to 
the meta-analysis not clearly indicated). 
 
Grade B (evidence from at least one controlled study 
without randomization or from one other type of 
quasi-experimental study or extrapolated recom-
mendation from meta-analysis of RCTs or at least 
one RCT; reference to the evidence not clearly indi-
cated). 
 
Deutsche Diabetes Gesell-
schaft (Germany), 2014 
Repeat training of patients with the objective of 
preventing ulcers. 
 
No evidence and no grading provided. 
Scottish Intercollegiate Guide-
lines Network (Scotland), 2013 
 
Foot care education is recommended as part of a 
multidisciplinary approach in all patients with dia-
betes. 
Grade B (see Table A3), 1+, 1++ (extrapolated evi-
dence from studies rated as 1++ or 1+, high quality 
meta-analyses, systematic reviews of RCTs, or RCTs 
with a very low risk of bias). Relevant citations pro-
vided: Dargis et al., 1999 [60], Rönnemaa et al., 1997 
[64]. 
 
Institute for Clinical Systems 
Improvement (USA), 2014  
 
Diabetes education should be offered to all patients 
with diabetes on diagnosis. 
 
Foot care education should be tailored to patients’ 
current knowledge, individual needs, and risk fac-
tors. 
 
Physical activity. 150 minutes a week of moderate-
intensity activity and resistance training 3 times a 
week unless contraindicated. 
 
Grade: high. Cited: Gillett et al., 2010 [65]. 
 
 
Guideline publisher indicated low-quality evidence, 
but no reference to evidence provided. 
 
 
No grading and no reference to evidence provided 
next to this recommendation. 
American Diabetes Associa-
tion (USA), 2014 
Provide general foot self-care education to all pa-
tients with diabetes. 
Grade B (only supportive evidence from well-
conducted cohort studies). No reference to the co-
hort study provided; only cited another guide-
line/review paper: Haas et al., 2012 [66]. 
 
International Working Group 
on the Diabetic Foot, 2015 
 
Patient education should be presented in a struc-
tured and organized manner. Education should be 
provided in several sessions over time, and pref-
erably using a mixture of methods. It is essential to 
evaluate whether the person with diabetes has un-
derstood the messages, is motivated to act, and has 
sufficient self-care skills. 
 
No specific evidence or grading provided for this 
recommendation (see Table A1). 
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Table A5 continued 
 
Guideline Recommendation Grading of evidence, as provided by the guide-
line publisher 
International Diabetes Federa-
tion, 2012 
 
Make patient-centered self-management education 
an integral part of all people with type 2 diabetes 
from time of diagnosis. On an ongoing basis, based 
on routine assessment of need. 
 
Use an appropriate multidisciplinary team to pro-
vide education to groups of people with diabetes, or 
individually if group work is considered unsuitable. 
Use modern communication technologies to ad-
vance methods of diabetes education. 
 
Provide ongoing self-management support. 
 
No grading provided. Cited: Norris et al., 2001 [67], 
Colagiuri et al., 2009 [68], NICE 2003 [69] (note: 
these are partly other guidelines). 
 
 
See above. 
 
 
 
 
 
See above. 
New Zealand Society for the 
Study of Diabetes (NZSSD) - 
Podiatry Special Interest 
Group, 2014 
 
Foot care education is recommended as part of a 
multi-disciplinary approach in all people with diabe-
tes.  
Grade B (very well-designed observational studies or 
extrapolated evidence from RCTs). Unknown from 
where this recommendation was derived. No refer-
ence to evidence provided.  
 
Table A6. Frequency of assessment/screening/risk stratification guidelines 
 
Guideline Recommendation Grading of evidence, as provided by the 
guideline publisher 
National Health and 
Medical Research 
Council (Australia), 
2011 
 
Assess all people with diabetes and stratify their risk of develop-
ing foot complications as follows: 
 
1. Low-risk people with no risk factors and no previous history of 
foot ulcer/amputation: examine annually (expert opinion). 
 
2. Intermediate risk people with one risk factor (e.g. neuropathy, 
peripheral arterial disease, or foot deformity) and no previous 
history of foot ulcer/amputation: examine at least every 3 to 6 
months (expert opinion). 
 
3. High-risk people with two or more risk factors (neuropathy, 
peripheral arterial disease, or foot deformity) and/or a previous 
history of foot ulcer/amputation: include in foot protection pro-
gram, including foot care education, podiatry review, and appro-
priate footwear (expert opinion). 
 
Grade C. Body of evidence provides some sup-
port for recommendations, but caution should be 
applied. Cited: McCabe et al., 1998 [46].  
Canadian Diabetes 
Association (Can-
ada), 2013 
In people with diabetes, foot examination by healthcare provid-
ers should be an integral part of diabetes management to iden-
tify persons at risk of ulceration and amputation. 
 
Foot examinations should be performed at least annually and at 
more frequent intervals in those at high risk. 
 
Grade C, level 3 (see Table A3). Cited: Feng et 
al., 2011 [44] 
 
 
Grade D, level 1 (see Table A1). Cited: Boulton 
et al., 2008 [8]. 
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Table A6 continued 
 
Guideline Recommendation Grading of evidence, as provided by the 
guideline publisher 
 
NICE, 2014 
 
Low current risk with normal sensation, palpable pulses: arrange 
management plan, including foot care education and annual re-
view. 
 
Increased risk with neuropathy, absent pulses, or another risk 
factor: every 3-6 months (at each review) inspect patients’ feet, 
consider need for vascular assessment, evaluate footwear, and 
enhance foot care education. 
 
High risk with neuropathy or absent pulses plus deformity, skin 
changes, or previous ulcer: every 1-3 months (at each review): 
inspect patients’ feet, consider need for vascular assessment, 
evaluate and ensure the appropriate provision of intensified foot 
care education, specialist footwear and insoles, and skin and nail 
care. 
 
Ulcerated foot or foot care emergencies (new ulceration, swell-
ing, discoloration): refer to multidisciplinary foot care team 
within 24 hours (as a minimum, investigate and treat vascular 
insufficiencies, initiate and supervise wound management, use 
dressings and debridement as indicated, use systemic antibiotic 
therapy for cellulitis or bone infection as indicated, ensure an 
effective means of distributing foot pressures, including special-
ist footwear, orthotics, and casts, try to achieve optimal glucose 
levels, and control risk factors for cardiovascular disease). 
 
The team should comprise highly trained specialist podiatrist 
and orthotist, nurses with training in dressing of diabetic foot 
wounds, and diabetologist with expertise in lower limb complica-
tions. They should have unhindered access for managing major 
wounds, urgent inpatient facilities, antibiotic administration, 
community nursing, microbiology, diagnostic and advisory ser-
vices, orthopedic/podiatric surgery, vascular surgery, radiology, 
and orthotics. Patients who may benefit from recvascularization 
should be referred promptly. 
 
Patients with non-healing ulcers should receive intensive sys-
temic antibiotic therapy. 
 
 
Use of best wound dressings, closely monitored, and dressings 
changed regularly dead tissue should be carefully removed. To-
tal contact casting may be considered for people with ulcers, 
unless there is severe ischemia. 
 
Grade A (see Table A1). No specific evidence 
provided. 
 
 
Grade C (see Table A1). No specific evidence 
provided. 
 
 
 
Grade C (see Table A1). No specific evidence 
provided. 
 
 
 
 
 
Grade D (see Table A2). No specific evidence 
provided. 
 
 
 
 
 
 
 
 
Grade D (see Table A2). No specific evidence 
provided. 
 
 
 
 
 
 
 
 
Grade C, 1b (extrapolated evidence from meta-
analysis of RCTs or at least one RCT). No refer-
ence to evidence provided. 
 
Grade B, 1b (evidence from at least one con-
trolled study without randomization, or from at 
least one other type of quasi-experimental study, 
or extrapolated recommendation from meta-
analysis of RCTs or one RCT). No reference to 
evidence provided. 
 
 Diabetic Foot Screening Guidelines The Review of DIABETIC STUDIES  177 
  Vol. 13 ⋅ No. 2-3 ⋅ 2016 
 
www.The-RDS.org  Rev Diabet Stud (2016) 13:158-186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A6 continued 
 
Guideline Recommendation Grading of evidence, as provided by the 
guideline publisher 
 
Deutsche Diabetes 
Gesellschaft (Ger-
many), 2014 
 
 
Feet and footwear should be checked as follows: 
Risk category 0: no sensory neuropathy, no PAD: annual exami-
nation. 
Risk category 1: sensory neuropathy with or without deforma-
tion: examination every 3-6 months. 
Risk category 2: PAD with or without sensory neuropathy: ex-
amination every 2-3 months by a specialist. 
Risk category 3: previous ulcer or amputation: examination 
every 1-2 months by specialist. 
 
 
No evidence and no grading provided by guide-
line publisher. 
 
Scottish Intercolle-
giate Guidelines 
Network (Scotland), 
2013 
 
 
All patients with diabetes should be screened to assess their risk 
of developing a foot ulcer. 
 
 
 
 
 
 
 
Low risk (absence of risk factors, i.e. no loss of sensation, no 
signs of peripheral vascular disease, and no other risk factors): 
annual screening by a trained healthcare professional, agreed 
self-management plan, provision of written and verbal education 
with emergency contact numbers, provision of appropriate ac-
cess to podiatrist if required. 
 
Moderate risk (one risk factor present, e.g. loss of sensation or 
signs of peripheral vascular disease (PVD) without callus or de-
formation): annual assessment by a podiatrist, agreed and tai-
lored management/treatment plan by podiatrist according to 
patient’s needs, provision of written and verbal education with 
emergency contact numbers. 
 
High risk (previous ulceration or amputation or more than one 
risk factor present, e.g. loss of sensation, signs of PVD with cal-
lus or deformation): annual assessment by a specialized podia-
trist, agreed and tailored management/treatment plan by podia-
trist according to patient’s needs, provision of written and verbal 
education with emergency contact numbers, referral for special-
ist intervention if required. 
 
Active: referral to and management by a member of a multidis-
ciplinary foot team, agreed and tailored management/treatment 
plan by podiatrist according to patient’s needs, provision of writ-
ten and verbal education with emergency contact numbers, re-
ferral for specialist intervention if required. 
 
 
Grade A (at least one meta-analysis, systematic 
review, or RCT rated as 1++, directly applicable 
to the target population; or a body of evidence 
consisting principally of studies rated as 1+, di-
rectly applicable to the target population, and 
demonstrating overall consistency of results.). 
Relevant citation provided: Crawford et al., 2007 
[70]. 
 
Grade C (a body of evidence including studies 
rated as 2+, directly applicable to the target popu-
lation and demonstrating overall consistency of 
results; or extrapolated evidence from studies 
rated as 2++).  Relevant citation provided: Abbott 
et al., 2002 [45]. 
 
Grade C (see above, Abbott et al., 2002 [45]. 
 
 
 
 
 
 
Grade C (see above, Abbott et al., 2002 [45]. 
 
 
 
 
 
 
 
Grade C (see above, Abbott et al., 2002 [45]. 
Institute for Clinical 
Systems Improve-
ment (USA), 2014  
 
Prevent microvascular complications through annual and 
biannual foot risk assessments and foot care counseling. 
Foot care specialist: consultation of a specialist is suggested if 
the patient 1) is unable to care properly for his own feet, 2)  
needs prescriptive footwear, or 3) has more serious problems 
such as foot deformations (e.g. Charcot), infected lesions, ul-
cers, deformed nails, or thick calluses. 
Vascular specialist/surgeon: consider referral if patient has 
symptoms of PVD such as loss of pulses and/or claudicaton. 
 
No grading and no reference to evidence pro-
vided next to the recommendations. 
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Table A6 continued 
 
Guideline Recommendation Grading of evidence, as provided by the 
guideline publisher 
 
American Diabetes 
Association (USA), 
2014 
 
All patients with diabetes should receive annual foot examina-
tions to identify risk factors predictive of ulcers and amputations. 
Examinations should include inspection and assessment of foot 
pulses and loss of protective sensation testing. 
 
Provide foot self-care education to all patients. 
 
For patients with foot ulcers and high-risk feet, use multidisci-
plinary approach. Refer patients to foot care specialist for life-
long surveillance if they smoke, have LOPS, structural abnor-
malities, or history of prior lower extremity complications. 
 
Include history of claudication and assessment of pedal pulses in 
initial PVD screening. Also, consider obtaining ABPI. 
 
 
Refer further vascular assessment patients with positive ABPI or 
significant claudication. Consider exercise, medications, and 
surgical options. 
 
 
Grade B (supportive evidence from well-
conducted cohort studies). No reference to the 
cohort study provided; only cited another guide-
line/review paper: Haas et al., 2014 [66]. 
 
Grade B (see above, Haas et al., 2014 [66]). 
 
Grade B (see above, Haas et al., 2014 [66]). 
 
 
 
 
Grade C (as supportive evidence from poorly 
controlled or uncontrolled studies). No reference 
to evidence provided. 
 
Grade C. No reference to evidence provided. 
 
International Work-
ing Group on the 
Diabetic Foot, 2015 
 
 
5 key elements: 
1. Regular inspection and examination of the at-risk foot. 
All people with diabetes should be examined at least once a year 
for potential foot problems. Patients with risk factors should be 
examined more frequently (1-6 mo). Patients should be exam-
ined in lying and standing position. Shoes and socks should be 
inspected. 
2. Identification of the at-risk foot: patients should be as-
signed to a risk category. Neuropathy assessed using 10 g 
monofilament, 128 Hz tuning fork, pin prick, cotton wool, and 
reflexes. Also, vascular status check for claudication, rest pain, 
and pedal pulses. Skin: color, temperature, edema. Bones and 
joints: deformations or bony prominences. History: previous 
ulceration/amputation, previous foot education, social isolation, 
poor access to healthcare, bare-foot walking. 
3. Education of patient and family: should be provided in 
several sessions over time, preferably using a mixture of meth-
ods, including evaluation of persons with diabetes for sufficient 
self-care skills, motivation, and knowledge. Healthcare providers 
should receive periodic education to improve care for high-risk 
individuals. 
4. Appropriate footwear. 
5. Treatment of non-ulcerative pathology: in high-risk pa-
tients, callus and nail and skin pathology should be treated regu-
larly by foot care specialist. Foot deformations should be treated 
by orthosis. 
3 levels of foot care management needed:  
Level 1: general practitioner, podiatrist, diabetic nurse. 
Level 2: diabetologist, surgeon, podiatrist diabetic nurse. 
Level 3: specialized foot center with multiple disciplines special-
ized in diabetic foot care. 
 
 
No specific evidence or grading provided for this 
recommendation (see Table A1). 
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Table A6 continued 
 
Guideline Recommendation Grading of evidence, as pro-
vided by the guideline pub-
lisher 
 
International Diabetes 
Federation, 2012 
 
 
Assess feet of people with diabetes as part of an annual review for lesions, which 
require active treatment, and for risk factors, ulcers, and amputations: 
 1. History of previous foot ulceration or amputation, symptoms of peripheral ar-
terial disease, physical or visual difficulty in self-foot- care. 
2. Foot deformation (hammer or clawed toes, bone prominences); visual evi-
dence of neuropathy (dry skin, dilated veins) or incipient ischemia; callus; nail 
deformity or damage; footwear. 
3. Detection of neuropathy by 10 g monofilament (or 128 Hz tuning fork); a bio-
thesiometer is an option for quantitative assessment (cut-off point for ulcer risk > 
25 volts); non-traumatic pin-prick. 
4. Palpation of foot pulses (dorsalis pedis and posterior tibial). Doppler an-
kle:brachial pressure ratio (< 0.9 for occlusive vascular disease) may be used 
where pulses are diminished to quantify the abnormality. 
 
Discuss reasons for foot review with each person with diabetes as part of the 
foot-care educational process. Agree on a foot-care plan based on the findings of 
the annual foot review with each person with diabetes. 
Assess and provide necessary foot-care education according to individual needs 
and risks of ulcer and amputation. 
Classify risk of ulcer and amputation according to findings of the foot assess-
ment: 
1. No added risk: no risk factors and no previous history of foot ulcer or amputa-
tion. 
2. At risk: one risk factor and no previous history of foot ulcer or amputation. 
3. High risk: two or more risk factors. Previous ulcer or amputation (very high 
risk). Manage according to risk classification level: 
No added risk:  provide foot-care education. 
At risk: arrange regular review, approximately every 6 months, by foot-care team. 
 
At each review: 
1. Inspect both feet: ensure provision of local management. 
2. Evaluate footwear: provide appropriate advice. 
3. Enhance foot-care education. 
High-risk patients: arrange frequent review every 3-6 months by foot-care team. 
At each review: 
1. Inspect both feet: ensure provision of local management, as indicated. 
2. Evaluate footwear: provide advice and specialist insoles and shoes if indicated. 
3. Consider need for vascular assessment or referral if indicated. 
4. Evaluate and ensure the appropriate provision of intensified foot-care educa-
tion. 
 
People with foot ulceration or infection should receive the following manage-
ment: refer to multidisciplinary foot-care team within 24 hours for: 
1. Appropriate wound management, dressings, and debridement if indicated. 
2. Classify infections as follows: mild (superficial with minimal cellulitis), moder-
ate (deeper than skin or more extensive cellultis), severe (accompanied by sys-
temic signs of sepsis). Consideration of systemic antibiotic therapy (often longer 
term) for extensive cellulitis or bone infection if indicated, generic penicillins, 
macrolides, clindamycin and/or metronidazole if indicated as first-line medica-
tions, with ciprofloxacin or co-amoxicllin as examples of second-line medications. 
3. Probing of bone, radiology and scans, magnetic resonance imaging, and bi-
opsy if indicated for suspected osteomyelitis. 
4. Reduce weight, relief of pressure (walking with crutches, rest), and optimal 
pressure distribution (casting if indicated and not contraindicated) 
5. Investigation and treatment (referral) for vascular insufficiency. 
6. Specialist footwear and orthotic care (e.g. insoles), and individualized discus-
sion on prevention of recurrence, when ulcer has healed. 
7. Optimal blood glucose control. 
 
No grading and no evidence 
provided by the guideline pub-
lisher. Cited are only other 
guidelines: NHMRC 2011 [9], 
SIGN 2013 [16], Bakker et al. 
2012 [21], ADA 2014 [19], 
NICE 2014 [12], CDA 2013 [11] 
(partly newer versions of the 
papers). 
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Table A6 continued 
 
Guideline Recommendation Grading of evidence, as pro-
vided by the guideline pub-
lisher 
 
 
 
Limited care: 
Risk assessment and classification as for recommended care, but with sensory 
assessment by 10 g monofilament or tuning fork, with or without non-traumatic 
disposable pin-prick, and peripheral circulation assessment by palpation of pedal 
pulses. 
Classification of infection as for recommended care, but antibiotic therapy with 
generic penicillins, macrolides, and/or metronidazole, given intravenously for 
deep tissue infections, and adjusted by response or culture results. 
Vascular referral according to findings and local revascularization facilities. 
 
Comprehensive care: 
The principles are as for recommended care, but the multidisciplinary foot-care 
team can be enhanced by on-site inclusion of vascular surgeons, orthopedic sur-
geons, orthotists, social workers, and psychologists. Foot pressure distribution 
measurements may be carried out. Sophisticated vascular scanning and an-
giography should be available to the foot-care team. 
 
 
 
 
New Zealand Society 
for the Study of Dia-
betes (NZSSD) - Po-
diatry Special Interest 
Group, 2014 
 
All people with diabetes should be screened for foot disease by a health care pro-
fessional. Screening should occur from the time of diagnosis on, and then at least 
once per year, if there are no features indicating a high-risk foot. More frequent 
examinations (every 3-6 mo) should be carried out if there are features of a high-
risk foot. 
 
 
Grade D (evidence by non-
analytical studies or expert 
opinion). However, no refer-
ence to evidence provided next 
to the recommendation. 
 
Legend: ABPI – ankle brachial pressure index. LOPS – loss of protective sensation. PVD – peripheral vascular disease. 
Table A7. Limited joint mobility guidelines 
 
Guideline Recommendation Grading of evidence, as provided by 
guideline publisher 
National Health and Medical 
Research Council (Australia), 
2011 
Use foot deformity score to assess limited joint mobility. Grade C (body of evidence provides some 
support for recommendation, but should be 
applied with caution). Cited: Abbott et al., 
2002 [45]; Pham et al., 2000 [47]; Leese et 
al., 2006 [43]. 
 
Canadian Diabetes Association 
(Canada), 2013 
Assessment by healthcare providers should include as-
sessment of structural abnormalities, including range of 
motion of ankles and toe joints.  
 
Grade D, level 4 (see Table A1). Cited: 
Boulton et al., 2008 [8]. 
NICE, 2014 Evaluation of musculoskeletal conditions on an annual 
basis is important for the detection of feet at elevated risk 
of ulceration. 
 
Level of evidence: 1b (evidence from at least 
one RCT). Cited: Pham et al., 2000 [47]. 
Deutsche Diabetes Gesellschaft 
(Germany), 2014 
 
Examination of both feet for limited joint mobility. No evidence and no grading provided. 
Scottish Intercollegiate Guide-
lines Network (Scotland), 2013 
Simple tests to assess presence of significant structural 
abnormalities. 
 
Grade 2++ (see Table A1). Relevant citation: 
Abbott et al., 2002 [45]. 
Institute for Clinical Systems 
Improvement (USA), 2014  
Foot examination should include assessment of limited 
joint mobility. 
 
Low-quality evidence. No reference to evi-
dence provided by guideline publisher. 
American Diabetes Association 
(USA), 2014 
Musculoskeletal assessment should include evaluation of 
any deformation. 
 
No grading provided. Cited: Boulton et al., 
2008 [8]. 
International Working Group on 
the Diabetic Foot, 2015 
 
Evaluate loss of joint mobility. No specific evidence or grading provided for 
this recommendation (see Table A1). 
International Diabetes Federa-
tion, 2012 
 
 No specific guideline provided 
New Zealand Society for the 
Study of Diabetes (NZSSD) - 
Podiatry Special Interest Group, 
2014 
 No specific guideline provided 
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Table A8. Recommendations for training of health care professionals 
 
Guideline Recommendation Grading of evidence, as provided by 
guideline publisher 
National Health and Medical 
Research Council (Australia), 
2011 
Any suitably trained healthcare professional may perform 
the risk assessment. 
Lowest level of evidence; expert opinion 
(evidence was absent or unreliable and ad-
vice was formulated based on clinical ex-
perience by experts in the field). 
 
Canadian Diabetes Association 
(Canada), 2013 
Education for caregivers and healthcare professionals. No grading provided. Cited: IWGDF, 
2012/2015 [20]. 
 
NICE, 2014 Health care professionals and other personnel involved in 
the assessment of diabetic feet should receive adequate 
training. 
Grade D (evidence from expert committee 
reports or opinions, clinical experience of 
respected authorities, or extrapolated evi-
dence of categories I, II, III). No reference to 
evidence provided. 
 
Deutsche Diabetes Gesellschaft 
(Germany), 2014 
 
Repeat training of caregivers. No grading and no evidence provided. 
Scottish Intercollegiate Guide-
lines Network (Scotland), 2013 
 
No clear recommendation provided.  
Institute for Clinical Systems 
Improvement (USA), 2014  
 
No clear recommendation provided.  
American Diabetes Association 
(USA), 2014 
No clear recommendation provided.  
International Working Group on 
the Diabetic Foot, 2015 
Physicians and other healthcare professionals should re-
ceive periodic education to improve care for high-risk in-
dividuals. 
 
No grading and no evidence provided. 
International Diabetes Federa-
tion, 2012 
Include in education teams healthcare professionals with 
specialist training in diabetes and delivery of education for 
people with diabetes. 
 
Level of evidence not clearly stated. 
New Zealand Society for the 
Study of Diabetes (NZSSD) - 
Podiatry Special Interest Group, 
2014 
 
No clear recommendation provided.  
 
 
Table A9. Self-monitoring and inspection of feet guidelines 
 
Guideline Recommendation Grading of evidence, as provided by 
guideline publisher 
National Health and Medical 
Research Council (Australia), 
2011 
Visual inspection of feet for structural abnormalities and 
ulceration.  
Grade C (evidence-based recommendation 
set up according to a systematic review of the 
literature. Body of evidence provides some 
support for recommendation, but it should be 
applied with caution. Note: no reference to 
evidence given by the guideline publisher). 
 
Canadian Diabetes Association 
(Canada), 2013 
Visual inspection of feet for skin changes, callus pattern, 
skin temperature, and evidence of infection. 
 
Grade D, level 4 (see Table A1). Cited: Boul-
ton et al., 2008 [8]. 
NICE, 2014 Self- monitoring and visual inspection of feet by people 
with diabetes should be encouraged.  
Grade D (evidence from expert committee 
reports or opinions, clinical experience of 
respected authorities, or extrapolated evi-
dence of categories I, II, III). No reference to 
evidence provided. 
 
Deutsche Diabetes Gesellschaft 
(Germany), 2014 
 
No clear recommendation provided.  
Scottish Intercollegiate Guide-
lines Network (Scotland), 2013 
All patients should be assessed and screened to assess 
their risk of developing foot ulcer.  
 
Grade B (see Table A3). 
 182  The Review of DIABETIC STUDIES Formosa et al. 
   Vol. 13 ⋅ No. 2-3 ⋅ 2016 
 
Rev Diabet Stud (2016) 13:158-186  Copyright © by Lab & Life Press/SBDR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A9 continued 
 
Guideline Recommendation Grading of evidence, as provided by 
guideline publisher 
 
Institute for Clinical Systems 
Improvement (USA), 2014  
 
 
Diabetes self-management or education by a qualified 
healthcare professional team (which may include a clini-
cian, dietitian, nursing staff, and a pharmacist) should be 
offered to patients diagnosed with diabetes. 
 
Inspection of feet for dermatological conditions, including 
color, sweating, infection, ulceration, callus, and blister-
ing. 
 
Daily self-inspection of feet for cuts, bruises, bleeding, 
redness, and nail problems. 
 
 
Quality of evidence: high  
Strength of recommendation: strong (further 
research is very unlikely to change confi-
dence in the estimate of the effect). 
Note: the grading by the guideline publisher 
is based on evidence that is not fully suitable 
to the recommendations as the evidence is 
on diabetes self-monitoring in general, but 
not the diabetic foot (e.g. Guicciardi et al., 
2014 [71], Steinsbekk et al., 2012 [72]).  
American Diabetes Association 
(USA), 2014 
Patients with diabetes and high-risk foot should under-
stand the importance of foot monitoring on a daily basis, 
and the proper care of the foot including nail and skin 
care. Hand palpation and visual inspection for surveillance 
of early foot problems. Patients with visual difficulties, 
physical constraints, or cognitive problems, which impair 
their ability to assess the condition of the foot, will need 
other people such as family members to assist in their 
care. 
 
No grading and no evidence provided next to 
the recommendation, only cited: ADA, 2003 
[50] (review article, part of guideline). 
International Working Group 
on the Diabetic Foot, 2015 
Regular callus removal appears to have a beneficial effect 
on the reduction of plantar pressure in the neuropathic 
diabetic foot. 
 
No specific evidence or grading provided for 
this recommendation (see Table A1). 
International Diabetes Federa-
tion, 2012 
 
No clear recommendation provided.  
New Zealand Society for the 
Study of Diabetes (NZSSD) - 
Podiatry Special Interest Group, 
2014 
 
No clear recommendation provided.  
 
 
Table A10. Multi-disciplinary diabetic foot care service guidelines 
 
Guideline Recommendation Grading of evidence, as provided by 
guideline publisher 
National Health and Medical 
Research Council (Australia), 
2011 
 
Patients with active diabetic foot disease should be re-
ferred to multidisciplinary diabetic foot care service. The 
team should comprise podiatrist, diabetes physician, or-
totist, diabetes nurse specialist, vascular surgeon, ortho-
pedic surgeon, radiologist, wound care nurse, and foot-
wear technician.  
 
Grade C (body of evidence provides some 
support for the recommendation, but caution 
should be applied). Cited: Horswell et al., 
2003 [73]; Rerkasem et al., 2009 [74]; Yesil et 
al., 2009 [75]. 
Canadian Diabetes Association 
(Canada), 2013 
 
Individuals who develop a foot ulcer should be managed 
by a multidisciplinary healthcare team with expertise in 
the management of foot ulcers to prevent recurrent foot 
ulcers and amputation. 
 
Grade C, level 3 (see Table A3). Cited: 
Dargis et al., 1999 [76]. 
NICE, 2014 Patients with active diabetic foot disease should be re-
ferred to multidisciplinary diabetic foot care service. The 
team should comprise a highly trained specialist, podia-
trist, and orthotist, nurses with training in dressing of dia-
betic foot wounds, and a diabetologist with expertise in 
lower limb complications. They should have unhindered 
access to management of major wounds, urgent inpatient 
facilities, antibiotic administration, community nursing, 
microbiology, diagnostic and advisory services, orthope-
dic/podiatric surgery, vascular surgery, radiology, and 
orthotics. 
Grade D (evidence from expert committee 
reports or opinions, clinical experience of 
respected authorities, or extrapolated evi-
dence of categories I, II, III). No reference to 
evidence provided. 
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